Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
MIAMI, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Defiance ETFs, a leader in thematic and leveraged exchange-traded funds, today announced the launch of the Defiance Daily Target 2X Short LLY ETF (Ticker: LLYZ). This fund provides investors with amplified 2X inverse daily exposure to the performance of Eli Lilly and Company (NYSE: LLY), enabling retail investors to seek enhanced downside exposure without the need for a margin account.
The specter of persistent inflation continues to loom large over the U.S. economy, keeping both consumers and policymakers on edge. Despite the Federal Reserve's aggressive campaign of interest rate hikes, the Personal Consumption Expenditures (PCE) price index, the central bank's preferred gauge of inflation, continues to run above its
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers.
Novo Nordisk's Wegovy cut cardiovascular risks significantly versus tirzepatide in a real-world study, showing fewer heart attacks, strokes, and deaths.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Elanco (NYSE:ELAN) and the best and worst performers in the pharmaceuticals industry.
A significant sector rotation is currently underway in equity markets, shifting investor capital away from the mega-cap technology stocks that dominated recent years towards more traditional value and cyclical segments. This trend, gaining significant momentum in 2025, sees sectors such as financial services, basic materials, healthcare, energy, and industrials outperforming,
The FDA now requires earlier MRI screening for Alzheimer's drug Leqembi to detect ARIA-E, a rare but serious side effect, aiming to improve treatment safety for patients.
The U.S. economy currently navigates an intriguing, yet precarious, path as hypothetical Q2 2025 data suggests a robust rebound in Gross Domestic Product (GDP) growth. This economic buoyancy, however, is shadowed by the persistent specter of inflation, with the Personal Consumption Expenditures (PCE) price index stubbornly holding above the
Prothena reported ASCENT trial data showing strong amyloid plaque reduction but high ARIA-E rates for Alzheimer's drug PRX012, prompting a shift in focus.
The global economic landscape remains deeply entrenched in a complex and often volatile trade conflict between the United States and China. What began in January 2018 as a series of targeted duties has escalated significantly through 2025, with both nations frequently adjusting and reinstating tariffs, creating a tangled web of
Novo Nordisk has entered into a collaboration with Replicate BioScience under which it will receive a defined, exclusive, worldwide license to use the latter’s self-replicating RNA platform to develop and commercialize treatments.
